Bucillamine-induced gigantomastia with galactorrhea and hyperprolactinaemia

Abstract

Gigantomastia is characterised by excessive breast growth and can occur as a rare, drug-induced adverse event. D-penicillamine is the most frequent cause of drug-induced gigantomastia. Only one case of gigantomastia due to bucillamine, an analogue of D-penicillamine, has been reported so far. We herein report a case of bucillamine-induced gigantomastia presenting with acute enlargement of the bilateral breasts and accessory breast tissue in the axillae 7 months after the start of bucillamine therapy. Awareness about this rare adverse event is important since bucillamine is still widely used in Japan and Korea.

Keywords:

• Bucillamine
• gigantomastia
• systemic sclerosis
• fibroadenoma
• prolactin

Patient consents

Written informed consent was obtained from the patient for publication of this case report and any accompanying images.

Ethical approval

Not Applicable.

Conflicts of interest

None

Correction Statement

This article has been republished with minor changes. These changes do not impact the academic content of the article.